SCHEMBL3784348

SCHEMBL3784348

CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3nc(C)c(C(C)(C)C)s3)cc2)ccn1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 13/20 0.65
EPHX2 P34913 3/20 0.65
KDR P35968 5/20 0.61
BRAF P15056 9/20 0.59
MAPK14 Q16539 4/20 0.58
HIPK4 Q8NE63 4/20 0.58
AURKB Q96GD4 3/20 0.58
PLK4 O00444 2/20 0.58
AURKA O14965 2/20 0.58
MAPK13 O15264 2/20 0.58
MAP4K4 O95819 2/20 0.58
ABL1 P00519 2/20 0.58
LCK P06239 2/20 0.58
FYN P06241 2/20 0.58
LYN P07948 2/20 0.58
RET P07949 2/20 0.58
SRC P12931 2/20 0.58
RPS6KB1 P23443 2/20 0.58
EPHA2 P29317 2/20 0.58
AXL P30530 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL257980 0.83 RAF1 (0.82) RAF1EPHX2KDRBRAFMAPK14
SCHEMBL1532339 0.80 RAF1 (0.77) RAF1EPHX2KDRBRAFMAPK14
SCHEMBL15624828 0.79 RAF1 (1.00) RAF1EPHX2KDRBRAFMAPK14
SCHEMBL6929979 0.79 GRM5 (0.75)
SCHEMBL6384891 0.79 RAF1 (0.78) RAF1EPHX2KDRBRAFABL1
SCHEMBL10163311 0.79 RAF1 (0.76) RAF1EPHX2KDRBRAFMAPK14
SCHEMBL12391532 0.79 RAF1 (0.76) RAF1EPHX2KDRBRAFMAPK14
SCHEMBL6387397 0.78 RAF1 (0.79) RAF1EPHX2KDRBRAFMAPK14
SCHEMBL6473889 0.78 RAF1 (0.63) RAF1EPHX2KDRBRAFMAPK14
SCHEMBL6382351 0.78 RAF1 (0.74) RAF1EPHX2KDRBRAFMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298385-A1 PROTEIN KINASE INHIBITORS USEFUL FOR TREATMENT OF CANCERS DU, XIAOMIN (CN) 2010-11-25 US disclosed
US-20100298385-A1 PROTEIN KINASE INHIBITORS USEFUL FOR TREATMENT OF CANCERS DU, XIAOMIN (CN) 2010-11-25 US disclosed
US-20100298385-A1 PROTEIN KINASE INHIBITORS USEFUL FOR TREATMENT OF CANCERS DU, XIAOMIN (CN) 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298385-A1 PROTEIN KINASE INHIBITORS USEFUL FOR TREATMENT OF CANCERS MAP3K6, MAP3K20, MAP3K5 RAF1 22/4885EPHX2 3960/4885KDR 576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.